- Home
- PGP vs APLT Comparison
PGP vs APLT Comparison
Compare PGP & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGP
- APLT
- Stock Information
- Founded
- PGP 2003
- APLT 2016
- Country
- PGP United States
- APLT United States
- Employees
- PGP N/A
- APLT N/A
- Industry
- PGP Finance Companies
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- PGP Finance
- APLT Health Care
- Exchange
- PGP Nasdaq
- APLT Nasdaq
- Market Cap
- PGP 97.1M
- APLT 178.6M
- IPO Year
- PGP N/A
- APLT 2019
- Fundamental
- Price
- PGP $8.50
- APLT $1.25
- Analyst Decision
- PGP
- APLT Buy
- Analyst Count
- PGP 0
- APLT 5
- Target Price
- PGP N/A
- APLT $4.13
- AVG Volume (30 Days)
- PGP 39.8K
- APLT 12.5M
- Earning Date
- PGP 01-01-0001
- APLT 11-06-2025
- Dividend Yield
- PGP 10.84%
- APLT N/A
- EPS Growth
- PGP N/A
- APLT N/A
- EPS
- PGP N/A
- APLT N/A
- Revenue
- PGP N/A
- APLT $121,000.00
- Revenue This Year
- PGP N/A
- APLT N/A
- Revenue Next Year
- PGP N/A
- APLT $5,935.35
- P/E Ratio
- PGP N/A
- APLT N/A
- Revenue Growth
- PGP N/A
- APLT N/A
- 52 Week Low
- PGP $5.83
- APLT $0.30
- 52 Week High
- PGP $7.81
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- PGP 44.72
- APLT 68.76
- Support Level
- PGP $8.44
- APLT $0.90
- Resistance Level
- PGP $8.70
- APLT $1.16
- Average True Range (ATR)
- PGP 0.07
- APLT 0.16
- MACD
- PGP -0.02
- APLT 0.03
- Stochastic Oscillator
- PGP 30.77
- APLT 95.83
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.